| Texto completo | |
| Autor(es): |
Otake, Andreia Hanada
[1, 2]
;
Mattar, Ana Lucia
[3]
;
Freitas, Helano Carioca
[1, 2]
;
Longo Machado, Camila Maria
[1, 2]
;
Nonogaki, Suely
[4]
;
Fujihara, Clarice Kazue
[3]
;
Zatz, Roberto
[3]
;
Chammas, Roger
[1, 2]
Número total de Autores: 8
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Fac Med, Dept Radiol, Lab Oncol Expt LIM 24, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Fac Med, Inst Canc Estado Sao Paulo, BR-01246903 Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Dept Clin Med, Lab Fisiopatol Renal LIM 16, BR-01246903 Sao Paulo - Brazil
[4] Inst Adolfo Lutz Registro, Sao Paulo - Brazil
Número total de Afiliações: 4
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Cancer Chemotherapy and Pharmacology; v. 66, n. 1, p. 79-87, MAY 2010. |
| Citações Web of Science: | 37 |
| Resumo | |
Purpose We evaluated the involvement of angiotensin II (AngII)-dependent pathways in melanoma growth, through the pharmacological blockage of AT1 receptor by the antihypertensive drug losartan (LOS). Results We showed immunolabeling for both AngII and the AT1 receptor within the human melanoma microenvironment. Like human melanomas, we showed that murine melanomas also express the AT1 receptor. Growth of murine melanoma, both locally and at distant sites, was limited in mice treated with LOS. The reduction in tumor growth was accompanied by a twofold decrease in tumorassociated microvessel density and by a decrease in CD31 mRNA levels. While no differences were found in the VEGF expression levels in tumors from treated animals, reduction in the expression of the VEGFR1 (Flt-1) at the mRNA and protein levels was observed. We also showed downregulation of mRNA levels of both Flt-4 and its ligand, VEGF-C. Conclusions Together, these results show that blockage of AT1 receptor signaling may be a promising anti-tumor strategy, interfering with angiogenesis by decreasing the expression of angiogenic factor receptors. (AU) | |
| Processo FAPESP: | 98/14247-6 - Center for Research on Cell-Based Therapy |
| Beneficiário: | Marco Antonio Zago |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |
| Processo FAPESP: | 06/60200-0 - Primeiros projetos |
| Beneficiário: | Andréia Hanada Otake |
| Modalidade de apoio: | Auxílio à Pesquisa - Programa Primeiros Projetos |